Abstract
Numerous genetic variants have been studied in the context of antiplatelet responsiveness, particularly for aspirin and clopidogrel. The majority of these variants have failed to demonstrate any measurable level of clinical validity with the exception of the CYP2C19*2 allele. Several studies have identified a link between CYP2C19*2 carriers and decreased clopidogrel responsiveness as assessed by platelet reactivity testing and clinical outcomes. The FDA boxed warning and strong evidence of the CYP2C19*2 allele provide a compelling indication to alter treatment when genotype information is available. However, several questions remain and universal genotyping cannot be recommended at this time without further studies that establish the clinical utility of genomic testing for clopidogrel.
Keywords: Antiplatelet agents, aspirin, clopidogrel, clopidogrel variability, CYP2C19, pharmacogenomics, polymorphism, prasugrel, allele, antithrombotic
Current Drug Targets
Title: Progress of Antiplatelet Pharmacogenomics
Volume: 12 Issue: 12
Author(s): Julie H. Oestreich
Affiliation:
Keywords: Antiplatelet agents, aspirin, clopidogrel, clopidogrel variability, CYP2C19, pharmacogenomics, polymorphism, prasugrel, allele, antithrombotic
Abstract: Numerous genetic variants have been studied in the context of antiplatelet responsiveness, particularly for aspirin and clopidogrel. The majority of these variants have failed to demonstrate any measurable level of clinical validity with the exception of the CYP2C19*2 allele. Several studies have identified a link between CYP2C19*2 carriers and decreased clopidogrel responsiveness as assessed by platelet reactivity testing and clinical outcomes. The FDA boxed warning and strong evidence of the CYP2C19*2 allele provide a compelling indication to alter treatment when genotype information is available. However, several questions remain and universal genotyping cannot be recommended at this time without further studies that establish the clinical utility of genomic testing for clopidogrel.
Export Options
About this article
Cite this article as:
H. Oestreich Julie, Progress of Antiplatelet Pharmacogenomics, Current Drug Targets 2011; 12 (12) . https://dx.doi.org/10.2174/138945011797635849
DOI https://dx.doi.org/10.2174/138945011797635849 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress and Post-Stroke Depression: Possible Therapeutic Role of Polyphenols?
Current Medicinal Chemistry Toll-like Receptors and Diabetes Complications: Recent Advances
Current Diabetes Reviews PPARs and Diabetes-Associated Atherosclerosis
Current Pharmaceutical Design Cardiovascular Risk Factors and Dietary Patterns
Current Nutrition & Food Science Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents
Current Pharmaceutical Design Intravenous Antihypertensives within Cardiovascular-Based Continuity of Care
Current Vascular Pharmacology Editorial [Hot Topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Hypertension-Related Disorders (Executive Guest Editor: Aurelio Leone)]
Current Pharmaceutical Design Lipoprotein-associated Phospholipase A2: A Potential Therapeutic Target for Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders Idarucizumab: Clinical Role of a Novel Reversal Agent for Dabigatran
Cardiovascular & Hematological Disorders-Drug Targets Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
Current Vascular Pharmacology Meet Our Associate Editor
Current Cardiology Reviews Bacterial Urease and its Role in Long-Lasting Human Diseases
Current Protein & Peptide Science NMR Based Metabolomics: An Exquisite and Facile Method for Evaluating Therapeutic Efficacy and Screening Drug Toxicity
Current Topics in Medicinal Chemistry Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Recent Patents on Nanotechnology The Roles of MicroRNAs in Heart Diseases: A Novel Important Regulator
Current Medicinal Chemistry microRNA in Chondrogenesis, Cartilage and Osteoarthritis
Current Rheumatology Reviews Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry Abnormal Insulin Signaling: Early Detection of Silent Coronary Artery Disease-Erectile Dysfunction?
Current Pharmaceutical Design Antidyslipidemic Capacity of <i>Cleome arabica</i> (L.) in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research